Testing a treatment to help clear genital high-risk HPV
Part of Infections, Women’s health & pregnancy clinical trials.
This trial studies 2LPAPI® to see if it helps the body clear high-risk HPV infections in the cervix. It may be an option if you have a current HPV infection with mild/early abnormal cervical findings and can complete follow-up for about a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 25–45
- You are not pregnant or breastfeeding, and you can use effective birth control during the study
- Your recent cervical tests show either normal or mild changes (no HSIL, and no CIN II/III)
- You have a current high-risk HPV infection based on today’s cervical sample
- You can stay in follow-up for 12 months and are able to attend study visits
- You should not have had HPV vaccination in the last month or joined another study in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ACU-D1 for people with HIV who have high-grade abnormal cell growth (HSIL) on their vulva or perianal area. The goal is to see if the drug can help treat these HPV-related lesions.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
This study is testing a vaginal gel that might help restore the health of the cervix in women who have HPV. If you have HPV and your cervical cells are normal or only mildly abnormal, you may be able to join.
This trial tests an antibacterial liquid (Paiteling®) to see if it can clear a persistent high-risk HPV infection of the cervix. It may be an option for women whose HPV has lasted 2 years or more and whose cervical biopsy shows only mild changes.
This study tests a new vaginal medication (Dysplasix) to treat mild cervical cell changes caused by high-risk HPV. The goal is to see if this treatment can help your body clear the virus and prevent these changes from getting worse.
Hear when a new Human Papilloma Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.